| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 07/27/2000 | WO2000042856A1 Activation of regulatory t cells by alpha-melanocyte stimulating hormone |
| 07/27/2000 | WO2000025814A3 Component for vaccine against serogroup b meningococci |
| 07/27/2000 | WO2000023592A3 Minimal promoters and uses thereof |
| 07/27/2000 | WO2000023574A3 Hepatitis a vaccines |
| 07/27/2000 | WO2000012684A3 Temperature-sensitive and cold-adapted human parainfluenza virus type 2 (hpiv-2) and vaccines based on such virus |
| 07/27/2000 | WO2000009699A9 Method for producing yeast expressed hpv types 6 and 16 capsid proteins |
| 07/27/2000 | WO2000009159A9 Compositions of cpg and saponin adjuvants and methods thereof |
| 07/27/2000 | WO2000005253A9 Antagonists specific for the corticotropin-releasing factor receptor type 2 (crfr2) |
| 07/27/2000 | WO1999064033A9 Phosphodiesterase-v modulator drugs and their uses |
| 07/27/2000 | CA2361124A1 Vaccine-mediated treatment of neurological disorders |
| 07/27/2000 | CA2360667A1 Neisseria meningitidis basb054 polypeptides and encoding polynucleotides and uses thereof |
| 07/27/2000 | CA2360658A1 Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies |
| 07/27/2000 | CA2360609A1 Basb055 polynucleotide and polypeptide from neisseria meningitidis. uses thereof |
| 07/27/2000 | CA2360062A1 Baff, inhibitors thereof and their use in the modulation of b-cell response |
| 07/27/2000 | CA2358914A1 Polypeptides derived from jnk3 |
| 07/27/2000 | CA2358899A1 Polypeptide |
| 07/27/2000 | CA2358584A1 Method of enhancing needleless transdermal powdered drug delivery |
| 07/27/2000 | CA2356681A1 Metalloproteinase-disintegrin family members: svph dnas and polypeptides |
| 07/27/2000 | CA2355168A1 Egg anti-inflammatory composition and method of treating and preventing inflammation |
| 07/27/2000 | CA2354375A1 Compositions and methods for the diagnosis and treatment of tumor |
| 07/26/2000 | EP1022338A2 Viral vaccines |
| 07/26/2000 | EP1022027A1 Tumor necrosis factor antagonists and their use in endometriosis |
| 07/26/2000 | EP1021725A1 Early detection of lysosomal storage disorders |
| 07/26/2000 | EP1021564A1 Process for detecting, extracting or removing human or mammalian cells with a disturbed cellular cycle regulation or unlimited proliferation or tumour-forming ability |
| 07/26/2000 | EP1021555A1 STABILIZATION OF $i(HELICOBACTER) UREASE |
| 07/26/2000 | EP1021553A2 Eukaryotic gene expression cassette and uses thereof |
| 07/26/2000 | EP1021548A1 Method for introducing and expressing rna in animal cells |
| 07/26/2000 | EP1021547A1 Papilloma virus capsomere vaccine formulations and methods of use |
| 07/26/2000 | EP1021546A1 Neutral sphingomyelinase |
| 07/26/2000 | EP1021545A2 Dengue virus antigens and treatment of dengue fever |
| 07/26/2000 | EP1021544A2 Chimeric vaccine against tick-borne encephalitis virus |
| 07/26/2000 | EP1021540A1 Human progesterone receptor complex p23-like protein |
| 07/26/2000 | EP1021537A1 T cell receptor-associated molecules (trams) and methods of use therefor |
| 07/26/2000 | EP1021535A2 Human cancer antigen ny eso-1/cag-3 and gene encoding same |
| 07/26/2000 | EP1021533A1 Nucleic acids coding for proteins capable of interacting with presenilins |
| 07/26/2000 | EP1021526A1 GENE DELETED RECOMBINANT FeLV PROVIRAL DNA FOR PRODUCTION OF VACCINES AGAINST FeLV |
| 07/26/2000 | EP1021464A1 Cellular receptor for hiv-1 vpr essential for g2/m phase transition of the cell cycle |
| 07/26/2000 | EP1021458A1 Helicobacter polypeptides and corresponding polynucleotide molecules |
| 07/26/2000 | EP1021202A1 Immunogenic peptides from the hpv e7 protein |
| 07/26/2000 | EP1021201A1 Use of growth differenciation factor-9 (gdf-9) as a contraceptive |
| 07/26/2000 | EP1021200A1 Methods and compositions for treating rheumatoid arthritis |
| 07/26/2000 | EP1021197A1 Implants comprising combinations of allogeneic cells for use in cancer treatment |
| 07/26/2000 | EP1021169A1 Active agent transport systems |
| 07/26/2000 | EP0832134B1 Anti-allergy bispecific molecules |
| 07/26/2000 | EP0769054B1 Immunomodulators |
| 07/26/2000 | EP0643583B1 Intraoperative, intravascular and endoscopic tumor and lesion detection and therapy |
| 07/26/2000 | EP0576522B1 A single dose vaccination system |
| 07/26/2000 | CN1261404A Lentivirus-Based gene transfer vectors. |
| 07/26/2000 | CN1261403A Surface exposed proteins from chlamydia pneumoniae |
| 07/26/2000 | CN1261374A Isolated nona- and decapeptides which bind to HLA molecules,and the use thereof |
| 07/26/2000 | CN1261286A CD154 blockade therapy for pancreatin islet tissue transplantation |
| 07/26/2000 | CN1261285A CD 154 blockade therapy for therapeutic protein inhibitor syndrome |
| 07/26/2000 | CN1261284A Use of a CD40 : CD154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection |
| 07/26/2000 | CN1261283A Multivalent in ovo avian vaccine |
| 07/26/2000 | CN1260998A Recombination adenovirus and its application in tumor treatment |
| 07/26/2000 | CA2296965A1 Use of bacterium for manufacture of a vaccine |
| 07/25/2000 | US6093809 Nucleotide sequence; anticarcinogenic and antiaging agents; diagnostic applications; evolutionary (e.g., phylogenetic) investigations |
| 07/25/2000 | US6093803 Method of producing aminoterminal propeptide of type 1 procollagen |
| 07/25/2000 | US6093802 Culturing cells transformed to express a nerve growth factor of specific amino acid sequence, activity, or weight and isolating protein; for treatment of alzheimer's/parkinson's diseases, amyotrophic lateral sclerosis, and nerve damage |
| 07/25/2000 | US6093794 Amino acid sequence of a 16 to 39 amino acids with modified n-and c-terminals; with viricidal and antifusogenic activity against retroviruses; prevention of human immunodeficiency virus transmission to uninfected cd4+ cells |
| 07/25/2000 | US6093699 Method for gene therapy involving suppression of an immune response |
| 07/25/2000 | US6093693 B cell activation |
| 07/25/2000 | US6093564 Methods and compositions for the selective modification of nucleic acids |
| 07/25/2000 | US6093558 Applying to a substrate an adhesive comprising a nonproteinaceous polymer of monomeric units comprising an aromatic moiety having hydroxyl group(s); contacting a bioactive protein (such as cell) with substrate to immobilize |
| 07/25/2000 | US6093557 Electrospraying apparatus and method for introducing material into cells |
| 07/25/2000 | US6093550 Unique associated Kaposi's sarcoma virus sequences and uses thereof |
| 07/25/2000 | US6093535 By analyzing genomic dna present in a sample of varicella virus and determining if dna satisfies eight characteristics |
| 07/25/2000 | US6093406 Vaccine for induction of immunity to malaria |
| 07/25/2000 | US6093405 Inactive but immunogenic cytokines, pharmaceutical compositions containing same, and methods of treating homeostatic disorders associated with an overproduction of cytokines |
| 07/25/2000 | US6093400 Modified HGP-30 peptides, conjugates, compositions and methods of use |
| 07/25/2000 | US6093394 Vaginal lactobacillus medicant |
| 07/25/2000 | US6093391 Peptide compositions containing polyoxyethylene-polyoxypropylene block copolymers that are useful in treatment of diseases and disorders with reduced side effects, ease in administering to desired target site, |
| 07/25/2000 | US6093381 Combining chemotherapeutic agent with lymph node lymphocytes which have been cultured under mitogenic stimulation conditions, or supernatant of it enriched in tumor reactive cells, administering such combination to the cancer patient |
| 07/25/2000 | CA2109727C Tumor rejection antigen precursors, tumor rejection antigens and uses thereof |
| 07/25/2000 | CA2094611C Hiv immunotherapeutics |
| 07/25/2000 | CA2049325C Peptide, immunogenic composition and vaccine or medicinal preparation; a method immunising a mammal against lhrh, and a method of improving the meat quality of pigs |
| 07/25/2000 | CA2015377C Autoantibodies which enhance the rate of a chemical reaction |
| 07/25/2000 | CA2010256C Protein anti-cancer agent |
| 07/20/2000 | WO2000042201A2 Human peptidases |
| 07/20/2000 | WO2000042194A2 Mutant hepatitis b surface antigen and testing |
| 07/20/2000 | WO2000042193A1 Neisseria meningitidis antigen |
| 07/20/2000 | WO2000042192A1 Neisseria meningitidis polypeptide basb052 |
| 07/20/2000 | WO2000042191A2 Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies |
| 07/20/2000 | WO2000042181A1 Minor histocompatibility antigens and their use in diagnosis and treatment of tumors |
| 07/20/2000 | WO2000042179A2 Complex-forming proteins |
| 07/20/2000 | WO2000042172A2 Human homologues of proteins regulated by circadian rhythms |
| 07/20/2000 | WO2000042170A1 Novel lrsg protein and nucleic acid molecules and uses therefor |
| 07/20/2000 | WO2000042074A1 Anti-ccr4 antibodies and methods of use therefor |
| 07/20/2000 | WO2000042073A1 Antagonists of tweak and of tweak receptor and their use to treat immunological disorders |
| 07/20/2000 | WO2000042070A1 Mammalian alpha-helical protein - 12 |
| 07/20/2000 | WO2000042068A2 Hiv related peptides |
| 07/20/2000 | WO2000042064A1 Peptides for inhibiting hpv e6 proteins |
| 07/20/2000 | WO2000041740A2 Particles for oral delivery of peptides and proteins |
| 07/20/2000 | WO2000041726A2 Noninvasive vascular therapy |
| 07/20/2000 | WO2000041724A1 Modulation of systemic memory t cell trafficking |
| 07/20/2000 | WO2000041722A1 Use of antibodies for anticancer vaccination |
| 07/20/2000 | WO2000041720A1 Improved saponin adjuvant compositions and methods relating thereto |
| 07/20/2000 | WO2000041719A1 Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders |
| 07/20/2000 | WO2000041717A2 Chorionic gonadotropin dna vaccines and methods |
| 07/20/2000 | WO2000041682A1 Lipophilic microparticles containing a protein drug or antigen and formulation comprising same |